Regulatory Review of Abbreviated Biologics Regulations in ICH Countries

ISSN： 2213-476X

Source： Applied Clinical Research, Clinical Trials and Regulatory Affairs, Vol.1, Iss.3, 2014-01, pp. : 169-175

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biologics Safety Preclinical, Clinical and Regulatory

By Hennig Renald

Expert Opinion on Drug Safety, Vol. 2, Iss. 6, 2003-11 ,pp. : 609-611

Informa Healthcare

Access to resources Recommend Favorite

Crohn's Disease: A Review of Current Treatment with a Focus on Biologics

By Panés Julián

Drugs, Vol. 67, Iss. 17, 2007-01 ,pp. : 2511-2537

Adis International

Access to resources Recommend Favorite

Book Review: Biosimilars—Design and Analysis of Follow-On Biologics, by Shein-Chung Chow

Journal of Biopharmaceutical Statistics, Vol. 24, Iss. 5, 2014-09 ,pp. : 1132-1135

Taylor & Francis Ltd

Access to resources Recommend Favorite

Devising a patent strategy to protect the IP of biologics in light of ambiguities, loopholes and pitfalls in the regulatory scheme

By Hsing Benjamin C Palla Sapna W

Pharmaceutical Patent Analyst, Vol. 2, Iss. 2, 2013-03 ,pp. : 153-155

Future Science

Access to resources Recommend Favorite

The use of electrocardiograms in clinical trials: a public discussion of the proposed ICH E14 regulatory guidance

By Cavero Icilio Crumb William

Expert Opinion on Drug Safety, Vol. 4, Iss. 4, 2005-07 ,pp. : 795-799

Informa Healthcare

Access to resources Recommend Favorite